PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc., a leader in MDMA-based therapeutics, has entered a significant sales agreement with Numinus Wellness Inc. to supply GMP LaNeo™ MDMA for an upcoming clinical trial in Canada, indicating a strong move towards advancing MDMA clinical practices. In addition to this milestone, PharmAla has showcased promising data from their ABA family of drug candidates at the Behaviour, Biology, and Chemistry conference, reflecting their ongoing commitment to research and development in the psychedelics space.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
